View More View Less
  • 1 Department of Microbiology Reference Laboratory and Biological Products, Ministry of Health General Directorate of Public Health, Ankara, Turkey
  • | 2 Ministry of Health Ankara, Turkey
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Abstract

The selection of therapeutic agent to be used for the treatment of multidrug-resistant bacteria is a major concern. Polymyxin B use has been commenced in Turkey, although its clinical breakpoint is not listed in the EUCAST. This study aimed to determine the correlation between the MIC values of polymyxin B and colistin. A total of 505 isolates, including 122 isolates of Escherichia coli and 383 isolates of Klebsiella pneumoniae were included in the present study. All the isolates were assessed for colistin and polymyxin B using the broth microdilution method. The categorical agreement in the E. coli isolates was 98.4%, and the rate of very major error was 33.3%. The categorical agreement in the K. pneumoniae isolates was 99.5%, the rate of major error was 0.36%, and the rate of very major error was 0.98%. In the evaluation of the essential agreement, 1.6% error in E. coli and 2.3% error in K. pneumoniae were observed. It was concluded that polymyxin B should never be used in the treatment of the isolates reported as colistin-resistant, and if the MIC values are above 4 mg/L in E. coli and K. pneumoniae. Our results indicate importance of reporting both polymyxin B and colistin susceptibility results of clinical isolates.

  • [1]

    Quintanilha JCF, Duarte NC, LIoret GR, Visacri MB, Mattos KPH, Dragosavac D, et al. . Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis. Int J Clin Pharm 2019; 41: 7480.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [2]

    Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. . Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6(9 ): 589601.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [3]

    Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. . Clinical and laboratory standards institute and European committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis 2020; 71(9 ): e523e529.

    • Search Google Scholar
    • Export Citation
  • [4]

    Central Asian and European Surveillance of antimicrobial resistance. Annual report 2020.

  • [5]

    Süzük YS, Şimşek H, Bakkaloğlu Z, Numanoğlu ÇY, Hekimoğlu CH, Kılıç S, et al. . National carbapenemase study group.: the epidemiology of carbapenemases in Escherichia coli and Klebsiella pneumoniae isolated in 2019 in Turkey. Mikrobiyol Bul 2021; 55(1 ): 116.

    • Search Google Scholar
    • Export Citation
  • [6]

    Süzük YS, Kaşkatepe B, Şimşek H, Sarıgüzel FM. High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey. Acta Microbiol Immunol Hung 2019; 66(1 ): 103112.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [7]

    European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 10.1, 2020.

    • Search Google Scholar
    • Export Citation
  • [8]

    Clinical and Laboratory Standard Institute (CLSI). M100-S25, Performance standards for antimicrobial susceptibility testing, 30th Edition, 2020b.

    • Search Google Scholar
    • Export Citation
  • [9]

    Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50(6 ): 19531958.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [10]

    Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014; 59(1 ): 8894.

  • [11]

    Deris ZZ, Akter J, Sivanesan S, Roberts KD, Thompson PE, Nation RL, et al. . A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. J Antibiot 2014; 67(2): 147151.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [12]

    Kunin CM, Craig WA, Kornguth M, Monson R. Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 1973; 226(1 ): 214224.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [13]

    Craig WA, Kunin CM. Significance of serum protein and tissue binding of antimicrobial agents. Annu Rev Med 1976; 27(1 ): 287300.

  • [14]

    Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, et al. . Framework for optimization of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015; 15: 225234.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [15]

    Ziaka M, Markantonis SL, Fousteri M, Zygoulis P, Panidis D, Karvouniaris M, et al. . Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother 2013; 57: 19381940.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [16]

    Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL. Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance. Antimicrob Agents Chemother 2016; 60(7 ): 39213933.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [17]

    Rigatto MH, Behle TF, Falci DR., Freitas T, Lopes NT, Nunes M, et al. . Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 2015; 70: 15521557.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [18]

    Abdul Rahim N, Cheah SE, Johnson MD, Yu H, Sidjabat HE, Boyce J, et al. . Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two ‘old’ antibiotics-polymyxin B and chloramphenicol. J Antimicrob Chemother 2015; 70: 25892597.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [19]

    Brolund A, Lagerqvist N, Byfors S, Struelens MJ, Monnet DL, Albiger B, et al. . European antimicrobial resistance genes surveillance network EURGen-net capacity survey group.: worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveill 2019; 24(9): 1900123.

    • Search Google Scholar
    • Export Citation
  • [20]

    CLSI performance Standards for antimicrobial susceptibility testing M 100. Wayne, PA: Clinical and Laboratory Standards Institute, 2020.

    • Search Google Scholar
    • Export Citation
  • [21]

    Humphries R. Colistin breakpoints for Pseudomonas aeruginosa and Acinetobacter spp. CLSI rationale document MR01. Wayne, PA: Clinical and Laboratory Standards Institute, 2018.

    • Search Google Scholar
    • Export Citation
  • [22]

    Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. Diagn Microbiol Infect Dis 2015; 83: 379381.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [23]

    Humphries RM. Susceptibility testing of the polymyxins: where are we now? Pharmacotherapy 2015; 35: 2227.

  • [24]

    Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest, A, Nation, RL, et al. . Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57: 37383745.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [25]

    Fan B, Guan J, Wang X, Cong Y. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model. PLoS One 2016; 11: e0157757.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 66 66 66
Full Text Views 10 10 10
PDF Downloads 16 16 16